CRISPR Ther­a­peu­tics claims safe­ty ad­van­tage in first big look at off-the-shelf CAR-T da­ta, but dura­bil­i­ty in ques­tion

CRISPR Ther­a­peu­tics CEO Samarth Kulka­rni thinks his com­pa­ny might have built the safest CAR-T ther­a­py yet.

The gene edit­ing biotech an­nounced the first ma­jor batch …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER